Search research articles
Contact Us
Filters
Showing results (1-10 of 27) with videos related to
Page
of 3
Sort By:
Journal of Aerosol Medicine and Pulmonary Drug Delivery
|
November 8, 2014
Safety, tolerability, and plasma exposure of tiotropium Respimat® in children and adults with cystic fibrosis
Michael W Konstan, Ashish Sharma, Petra Moroni-Zentgraf, et al.
Respiratory Medicine
|
February 10, 2015
Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma
Wolfgang Timmer, Petra Moroni-Zentgraf, Piet Cornelissen, et al.
Respiratory Medicine
|
March 16, 2013
Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD
Roger Abrahams, Petra Moroni-Zentgraf, Joe Ramsdell, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery
|
April 7, 2015
A Handling Study to Assess Use of the Respimat(®) Soft Mist™ Inhaler in Children Under 5 Years Old
Wolfgang Kamin, Marion Frank, Sabine Kattenbeck, et al.
Pulmonary Pharmacology & Therapeutics
|
January 1, 2017
Pharmacokinetics of tiotropium administered by Respimat<sup>®</sup> in asthma patients: Analysis of pooled data from Phase II and III clinical trials
Ashish Sharma, Huib A M Kerstjens, René Aalbers, et al.
Respiratory Research
|
June 4, 2014
Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma
Kai-Michael Beeh, Petra Moroni-Zentgraf, Othmar Ablinger, et al.
Respiratory Research
|
April 9, 2015
A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
Christian Vogelberg, Petra Moroni-Zentgraf, Migle Leonaviciute-Klimantaviciene, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
April 23, 2020
Tiotropium Respimat Efficacy and Safety in Asthma: Relationship to Age
Dennis E Doherty, Eugene R Bleecker, Petra Moroni-Zentgraf, et al.
The Journal of Allergy and Clinical Immunology
|
May 5, 2015
Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network meta-analysis
Eric D Bateman, Dirk Esser, Costel Chirila, et al.
Plos One
|
April 21, 2015
Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study
Ken Ohta, Masakazu Ichinose, Yuji Tohda, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 27) with videos related to
Sort By:
Page
of 3
Journal of Aerosol Medicine and Pulmonary Drug Delivery
|
November 8, 2014
Safety, tolerability, and plasma exposure of tiotropium Respimat® in children and adults with cystic fibrosis
Michael W Konstan, Ashish Sharma, Petra Moroni-Zentgraf, et al.
Respiratory Medicine
|
February 10, 2015
Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma
Wolfgang Timmer, Petra Moroni-Zentgraf, Piet Cornelissen, et al.
Respiratory Medicine
|
March 16, 2013
Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD
Roger Abrahams, Petra Moroni-Zentgraf, Joe Ramsdell, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery
|
April 7, 2015
A Handling Study to Assess Use of the Respimat(®) Soft Mist™ Inhaler in Children Under 5 Years Old
Wolfgang Kamin, Marion Frank, Sabine Kattenbeck, et al.
Pulmonary Pharmacology & Therapeutics
|
January 1, 2017
Pharmacokinetics of tiotropium administered by Respimat<sup>®</sup> in asthma patients: Analysis of pooled data from Phase II and III clinical trials
Ashish Sharma, Huib A M Kerstjens, René Aalbers, et al.
Respiratory Research
|
June 4, 2014
Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma
Kai-Michael Beeh, Petra Moroni-Zentgraf, Othmar Ablinger, et al.
Respiratory Research
|
April 9, 2015
A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
Christian Vogelberg, Petra Moroni-Zentgraf, Migle Leonaviciute-Klimantaviciene, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
April 23, 2020
Tiotropium Respimat Efficacy and Safety in Asthma: Relationship to Age
Dennis E Doherty, Eugene R Bleecker, Petra Moroni-Zentgraf, et al.
The Journal of Allergy and Clinical Immunology
|
May 5, 2015
Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network meta-analysis
Eric D Bateman, Dirk Esser, Costel Chirila, et al.
Plos One
|
April 21, 2015
Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study
Ken Ohta, Masakazu Ichinose, Yuji Tohda, et al.
Page
of 3